MOESM1 of In vitro biomechanical testing of the 3.5Â mm LCP in torsion: a comparison of unicortical locking to bicortical nonlocking screws placed nearest the fracture gap

Additional file 1. Relative implant deformation. Photograph demonstrating the relative amounts of plate deformation. Tangential lines extending from the screw tips have been inserted for illustrative purposes. Note the marked amount of torsional deformation for the ABL construct compared to all other constructs

MOESM1 of Consensus Diversity Plots: a global diversity analysis of chemical libraries

Additional file 1: Table S1. Scaffold diversity using scaled Shannon entropy at different numbers of most populated scaffolds. Table S2. Summary of the intra-library similarity distributions computed with Extended Connectivity/Tanimoto. Figure S1. Definition of molecular scaffold used in this work. Figure S2. Consensus Diversity Plots for the eight data sets and two subsets studied in this work using Extended Connectivity/Tanimoto. Figure S3. Consensus Diversity Plots using measures of scaffold diversity for the most populated scaffolds

Is low-dose aspirin therapy to prevent preeclampsia more efficacious in non-obese women or when initiated early in pregnancy?

<div><p></p><p><i>Objective</i>: Late timing of intervention and maternal obesity are potential explanations for the modest effect of aspirin for preeclampsia prevention. We explored whether low-dose aspirin (LDA) is more effective in women at increased risk when initiated before 16 weeks' gestation or given to non-obese women.</p><p><i>Methods</i>: Secondary analysis of a trial to evaluate LDA (60 mg/d) for preeclampsia prevention in high-risk women. Participants were randomized to LDA or placebo between 13 and 26 weeks. We stratified the effect of LDA on preeclampsia by (a) timing of randomization (< 16 or ≥ 16 weeks gestation) and (b) body mass index (BMI) class (non-obese and obese). The Breslow–Day test for homogeneity was used to assess for variations in effect of LDA across gestational age and BMI groups.</p><p><i>Results</i>: Of 2503 women, 461 (18.4%) initiated LDA < 16 weeks. LDA effect was not better when initiated < 16 weeks (RR: 0.93, 95% CI: 0.67–1.31) versus ≥ 16 weeks (RR: 0.90, 95% CI: 0.75–1.08), (<i>p</i> value for interaction = 0.87). Similarly, LDA effect was not better in non-obese (RR: 0.91, 95% CI: 0.7–1.13) versus obese women (RR: 0.89, 95% CI: 0.7–1.13), (<i>p</i> value for interaction = 0.85).</p><p><i>Conclusion</i>: LDA for preeclampsia prevention was not more effective when initiated < 16 weeks or used in non-obese women at risk for preeclampsia. No particular subgroup of women was more or less likely to benefit from LDA therapy.</p></div

Image_1_Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels.tif

IntroductionHemophilia A (HA) is the most common X-linked bleeding disorder, occurring in 1 in 5,000 live male births and affecting >1 million individuals worldwide. Although advances in protein-based HA therapeutics have improved health outcomes, current standard-of-care requires infusion 2-3 times per week for life, and 30% of patients develop inhibitors, significantly increasing morbidity and mortality. There are thus unmet medical needs requiring novel approaches to treat HA.MethodsWe tested, in a highly translational large animal (sheep) model, whether the unique immunological and biological properties of autologous bone marrow (BM)-derived mesenchymal stromal cells (MSCs) could enable them to serve as cellular delivery vehicles to provide long-term expression of FVIII, avoiding the need for frequent infusions.ResultsWe show that autologous BM-MSCs can be isolated, transduced with a lentivector to produce high levels of ovine (o)FVIII, extensively expanded, and transplanted into adult animals safely. The transplanted cells engraft in multiple organs, and they stably produce and secrete sufficient quantities of FVIII to yield elevated plasma FVIII levels for at least 15 weeks.DiscussionThese studies thus highlight the promise of cellular-based gene delivery approaches for treating HA.</p